BioNTech SE (ETR:22UA)
Germany · Delayed Price · Currency is EUR | Market Cap | 19.69B |
| Revenue (ttm) | 2.88B |
| Net Income (ttm) | -344.80M |
| Shares Out | n/a |
| EPS (ttm) | -1.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 917 |
| Average Volume | 64,473 |
| Open | 83.00 |
| Previous Close | 80.95 |
| Day's Range | 81.50 - 83.00 |
| 52-Week Range | 73.15 - 124.90 |
| Beta | 1.40 |
| RSI | 36.78 |
| Earnings Date | Nov 3, 2025 |
About BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph... [Read more]
Financial Performance
Financial StatementsNews
Mizuho's Jared Holz: There's not much value left in vaccine stocks
Jared Holz, Mizuho healthcare senior strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on pharmaceuticals, what new government vaccine panel recommendations mean for the stocks, and ...
BioNTech (BNTX) Stock Dips Amid Vaccine Safety Concerns
BioNTech (BNTX) Stock Dips Amid Vaccine Safety Concerns
Why BioNTech Stock Sank by More Than 7% Today
The type of vaccine it's most famous for might be cast in a very unflattering light in the very near future..
Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths
Shares of COVID-19 vaccine makers Pfizer Inc (NYSE: PFE), BioNTech SE ADR (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA) are trading lower Friday following a Washington Post report that Trump admini...
COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says
Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.
BioNTech (BNTX) Shares Decline by Nearly 10%
BioNTech (BNTX) Shares Decline by Nearly 10%
Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults
Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) reported topline Phase 3 results for their LP.8.1-adapted monovalent COMIRNATY (2025-2026 Formula) in high-risk adults . Among 100 participants...
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy
BioNTech SE (NASDAQ: BNTX) and Bristol Myers Squibb Co (NYSE: BMY) shared interim Phase 2 data on pumitamig (BNT327/BMS986545) plus chemotherapy in patients with untreated extensive-stage small cell...
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy
BioNTech SE BNTX and Bristol Myers Squibb Co BMY shared interim Phase 2 data on pumitamig (BNT327/BMS986545) plus chemotherapy in patients with untreated extensive-stage small cell lung cancer (ES-SCL...
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb ...
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Can
BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial
A next-generation cancer immunotherapy by BioNTech and partner Bristol Myers Squibb led to encouraging tumour shrinkage in a mid-stage trial on small cell lung cancer that has started spreading, the G...
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
MAINZ, Germany, and PRINCETON, USA, September 8, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today presented interim data from a global randomized...
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8. ...
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula | PFE Stock News
Pfizer, partner BioNTech say updated COVID shot shows better immune response
Pfizer and partner BioNTech said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one underlyi...
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced positive topline results from an ongoing Phase 3 clinical trial...
BioNTech's First Oncology Win: A Major Step, But Not A Game-Changer Yet
Why BioNTech Stock Crushed the Market Today
The company might be close to commercializing its most advanced pipeline program.
BioNTech (BNTX) Achieves Progress in Phase 3 Cancer Drug Trial
BioNTech (BNTX) Achieves Progress in Phase 3 Cancer Drug Trial
BioNTech (BNTX) Shares Surge on Promising Breast Cancer Drug Trial Results
BioNTech (BNTX) Shares Surge on Promising Breast Cancer Drug Trial Results
BioNTech (BNTX) Hits Milestone with Successful Phase 3 Cancer Trial
BioNTech (BNTX) Hits Milestone with Successful Phase 3 Cancer Trial
BioNTech Surges 10% On Promising Test Results For Its Cancer Smart Bomb
BioNTech stock surged Friday after its experimental breast cancer treatment met a pre-specified bar for success in a pivotal study.
BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data
BioNTech and DualityBio reported Phase 3 success ... Full story available on Benzinga.com
BioNTech rises as breast cancer drug shows positive phase 3 results
BioNTech, Duality score initial trial win with breast cancer precision drug
BioNTech and its partner Duality Biologics said on Friday that a late-stage trial testing their precision drug against a certain type of breast cancer reached its main goal of slowing down disease pro...
mRNA Biotechs - Long-Term Value Risks Abound
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...